IDT Biologika acquires Cambridge facility, expands Canadian operations
August 21, 2017 by Manufacturing AUTOMATION
Aug. 21, 2017 – IDT Biologika and Gallant Custom Laboratories, an IDT Biologika company serving the animal health industry, say its new facility will “significantly enhance” their vaccine development and manufacturing capabilities.
Gallant currently produces autogenous veterinary biologics at 1425 Bishop St. North in Cambridge, Ont. To accommodate the growing needs of customer and business partners, IDT Biologika will convert the newly-purchased nearby building into a vaccine manufacturing facility, expanding Gallant’s operations as early as next summer.
“We intend to raise the bar for manufacturing technology and innovation, capacity, and development of veterinary biologics in Canada,” said Andreas Kastenbauer, managing director of IDT and head of the company’s global Animal Health Division. “As we continue to expand our footprint across the Americas, veterinarians, farmers and government agencies in Canada and in the region are sure to reap important benefits from the breadth and depth of our capabilities that will emanate from this vaccine manufacturing hub in the years to come. We will begin renovations immediately.”
The nearly 32,000-square foot facility will support the commercial production of animal health vaccines, including antigen production, blending-filling-packaging, storage, a clean room lab, offices and meeting areas, and bacterial research. Automation and other high-tech equipment and computing capabilities are considered in construction and installation plans, says the company.
“This new facility will be a great boost for Canadian animal health and the local economy. Additionally, it offers tremendous expansion possibilities in the future to help us continue to meet the demands of a strategically important, growing market in the Americas,” said Jackie Gallant, founder and president of Gallant Custom Laboratories.
IDT says it plans to invest in the build-out and more than double the Gallant employee base over the next few years.